Relevance. Relapses and refractory course (r/r) develop in 10 % of children and adolescents with a newly diagnosed classical Hodgkin lymphoma (cHL). The basis for successful treatment of r/r cHL is morpho-immunohistochemical diagnostics and positron emission tomography, as well as the inclusion of targeted and immune drugs in the treatment regimen. Russian experience of intercenter interaction in the treatment of r/r cHL is small, so each new study is significant from a scientific and practical standpoint.The aim of the study is to present long-term results of r/r cHL treatment using targeted drugs, chemotherapy and autologous hematopoietic stem cell transplantation.Materials and methods. From 2003 to 2023, 73 patients with r/r cHL were included in the study. The age of the patients ranged from 5.5 to 18.6 years (median – 14.5 years). Second-line therapy was carried out according to the following regimens: ICE (n = 23; 31.5 %), ViGePP (n = 15; 20.5 %), DHAP (n = 6; 8.2 %), IEP/ABVD (n = 6; 8.2 %); 7 (9.6 %) patients underwent a change in treatment regimen due to a poor response to the first 2 courses of therapy. Sixteen (21.9 %) patients were treated according to the ViGePP regimen with the addition of brentuximab vedotin (6 injections).Results. The 10-year overall survival of patients was 76 ± 6 %, relapse-free survival (RFS) was 64 ± 6 %. When brentuximab vedotin was included in the therapy program, the RFS was higher – 83 ± 15.2 % (p = 0.09).Conclusion. The results of a joint cooperative study of two Russian clinics for the treatment of r/r cHL are presented. The data obtained allow us to state the high efficiency of second-line therapy regimens with brentuximab vedotin and subsequent autologous stem cell transplantation.
Immunotherapy is a promising method in the treatment of cancer. PD-1 (programmed cell death protein 1) receptor and its ligand, which contribute to the reactivation of T-cells exerting their cytotoxic function against the tumor, are one of the targets of antitumor drugs. The effectiveness of immune checkpoint inhibitors has been demonstrated in the treatment of melanoma and non-small cell lung cancer. The spectrum of side effects of antitumor immune drugs differs from the classical ones observed in the cytostatics treatment. Immune-mediated adverse events can affect multiple organs, including skin, gastrointestinal tract, endocrine and nervous systems, and lungs. Pneumonitis is a potentially life-threatening complication and often requires immediate administration of corticosteroids.This article presents the case of a patient with relapsed Burkitt lymphoma treated with nivolumab and R-ICE (rituximab, ifosfamide etoposide, carboplatin) scheme. The therapy was effective, but complicated by immune-mediated pneumonitis. Corticosteroids administration resolved this complication and anti-cancer treatment was completed. The following nivolumab administrations were free of side effects.
19 October 2021 in Russian Journal of Pediatric Hematology and Oncology
By the whole history of pediatric acute lymphoblastic leukemia (ALL) treatment protocols development, one of the World ideologist oforiginal science-based therapeutic approaches was German group BFM (Berlin–Frankfurt–Münster). It is not surprisingly that modernALL treatment protocols, developed by BFM group are high-effective and use in many countries. Understanding the probability of recovery ofoverwhelming ALL patients majority treated by ALL IC-BFM 2002 protocol, the Scientific-Practical Board of Ministry of Health of Russiain 2020 adopted a protocol as clinical recommendation for pediatric ALL treatment (ID:529).It the current issue BFM ALL treatment protocols evolution is presented and first Russian multicenter experience in pediatric ALL treatmentby ALL IC-BFM 2002 protocol. It was 408 pediatric and adolescents patients with primary ALL included the study. All of them were treated by ALL IC-BFM 2002 protocolfrom 01.11.2003 to 12.05.2021. Survival rate was estimated on 01.06.2021.ALL IC-BFM 2002 demonstrated a high efficiency in multicenter retrospective study. 15-year event-free survival was 83.7 ± 2.1 %, relapsefree survival – 88 ± 1.8 % and overall survival – 93.4 ± 1.4 %. So, ALL IC-BFM 2002 protocol could be realized in Russian clinics and giveresults similar to world’s leading medical centers.
19 January 2022 in Russian Journal of Pediatric Hematology and Oncology
Acute lymphoblastic leukemia is the most common tumor of childhood. Using of modern treatment chemotherapy regimens, we can reach about 90 % of 5-year survival. An important problem – patients with relapses of the disease, as well as children with the persistence of minimal residual disease (MRD), which is absolutely necessary in hematopoietic stem cell transplantation aspects. The possibilities of continuous intensive chemotherapy are limited by high toxicity, and therefore targeted drugs are used to achieve MRD-negative remission in children, in particular, a bispecific antibody – blinatumomab.This article presents our own experience of using blinatumomab in patients using various financial sources, the technical features of using within the federal medical center. Also, undesirable effects of the drug and their therapy are mentioned.
21 September 2020 in Russian Journal of Pediatric Hematology and Oncology
Packed red blood cells are important part of modern treatment recommendations of anemic syndrome in benign and malignant diseases of hematopoietic system in both adults and children. Special features of iron metabolism in the human body after erythrocytes-containing transfusions lead to its increased accumulation in organs and tissues and post-transfusion iron overload development. Clinical manifestation of post-transfusion iron overload varies, but in the absence of chelation therapy can lead to life-threatening complications. This literature review describes the main causes of iron overload, clinical features, and diagnosis and treatment of iron overload.
13 April 2022 in Russian journal of hematology and transfusiology
Introduction. The development of febrile neutropenia complicates the course of the post-chemotherapeutic period in many patients with acute leukemia. Febrile neutropenia — the most common complication of the post-chemotherapeutic period in patients with acute leukemia (AL), and the concomitant infectious complications can cause life-threatening conditions. Invasive fungal infections in AL patients during neutropenia can be extremely severe.Aim — to present a clinical observation and successful diagnosis and treatment of the rare fungal infection induced by fungi of the genus Fusarium in an immunocompromised patient.Main findings. A clinical observation, diagnosis and treatment of a rare fungal infection caused by the fungi of the Fusarium genus is presented. The taxonomic variety of Fusarium is given, and the morphological and molecular methods of diagnostics are highlighted. Special attention is given to the choice of appropriate antifungal therapy of fusariosis.